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The aim of this review is to provide evidence-based recommendations on the secondary
prevention of atherothrombotic ischemic stroke. Antiplatelets are the major therapy for the
secondary stroke prevention. The most commonly used antiplatelets agents are aspirin,
clopidogrel, and extended-release dipyridamole. A lot of progress had been made in last
years regarding aspirin resistance and genotyping of clopidogrel metabolism. According to
the results of the accomplished studies it is difﬁcult to broadly recommend one antithrom-
botic agent in favor of the other. Instead, a review of the currently published data suggests
the importance of focusing on the individualizing approach in antiplatelet therapy.
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INTRODUCTION
Reducing the high risk of a recurrent stroke is an important com-
ponent of the management of patients with ischemic stroke or a
recent transient ischemic attack (TIA). Recurrent strokes are par-
ticularly dangerous (Hankey et al., 2007). Approximately 60–70%
of ﬁrst recurrent strokes have the same mechanism as the incident
stroke (Shin et al., 2005).
Stroke patients often have coronary or peripheral artery dis-
ease (PAD), and increased risks of cardiovascular death. (Steg
et al., 2007). Therefore, secondary stroke prevention depends upon
stroke subtypes and concomitant cardiovascular disorders (Ohira
et al., 2006).
In patients with TIA or ischemic stroke of non-cardiac ori-
gin antiplatelets drugs are able to decrease the risk of stroke by
11–15%. And the composite risk of stroke, myocardial infarc-
tion (MI), and vascular death is 15–22% (Antithrombotic Trialists’
Collaboration, 2002).
This review focuses on evidence-based recommendations for
secondary prevention of atherothrombotic ischemic stroke.
ASPIRIN
Aspirin (Acetylsalicylic acid, ASA) has a long history in the area of
secondary stroke prevention. It is the main comparator agent in
many recurrent stroke prevention trials, and the subject of many
metareviews or systematic analyses. Aspirin is relatively safe, easy
to administer, and readily available.
Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) in
platelets by acetylating its serine-529 residue, thereby block-
ing thromboxane 2 (TXA2) and other eicosanoid production
from arachidonic acid. COX-1-dependent TXA2 inhibition lasts
throughout a platelet’s lifespan (7–10 days), thereby aspirin effects
are maintained with daily dosing intervals. Aspirin induced COX-
1 inhibition is rapid and irreversible (Roth and Calverley, 1994).
After a single 325mg dose of ASA, platelet COX-1 activity is
completely inhibited and recovers by about 10% per day, due to
nascent platelet release in the circulation.After a single dose, a peak
value is reached in about 1 h and then declines gradually, with a
half-life of about 2–3 h at antiplatelet doses (Brunton et al., 2005).
In meta-analysis of all randomized clinical trial (RCTs) con-
ducted in ischemic stroke or TIA patients comparing aspirin in
different doses to placebo, it was found that aspirin reduces the
risk of recurrent stroke and other major vascular events by 13%
(95% CI, 6–19%; Algra and van Gijn, 1999).
The overview analysis of an indirect comparisons between the
various doses of aspirin suggests that aspirin doses as low as
30mg/day to as high as about 1300–1500mg/day have the same
point estimate of efﬁcacy for recurrent stroke prevention, but
lower-dose aspirin use is associated with fewer side effects (The
Dutch TIA Trial Study Group, 1991). Some experts suggest an
aspirin dose of 75–81mg/day as one providing the best safety and
efﬁcacy balance for cardiovascular disease prevention (Campbell
et al., 2007).
The Antithrombotic Trialists’ Collaboration had summarized
the data from thousands of patients with stroke or TIA (mean
duration of 29months), those who had taken antiplatelet agents,
primarily aspirin, in clinical trials. The data shows that serious
vascular events are reduced by 36 per 1000 (P = 0.0001) driven
by a reduction of non-fatal stroke by 25 per 1000 (P = 0.0001)
with a smaller but signiﬁcant reduction of non-fatal MI by 6/1000
fewer (P = 0.0009) events (Antithrombotic Trialists’ Collabora-
tion, 2002).
The main adverse event in association with aspirin administra-
tion is bleeding complications.
Aspirin increases the risk of major bleeding by about 70% [risk
ratio (RR) 1.71 (95% CI, 1.41–2.08)]. Low-dose aspirin increases
the risk of major bleeding by 70%, but the absolute increase is
modest: 769 patients (95% CI, 500–1250) need to be treated with
aspirin to cause one additional major bleeding episode annu-
ally. The increased risk of bleeding is mainly due to an increase
in major gastrointestinal bleeding [RR 2.07 (95% CI, 1.61–2.66)
www.frontiersin.org July 2011 | Volume 2 | Article 36 | 1
Shulga and Bornstein Antiplatelets in secondary stroke prevention
with absolute annual increase 0.12% (0.07–0.19%)] and
intracranial bleeding [RR 1.65 (1.06–5.99); with absolute
annual increase 0.03% (0.01–0.08%; McQuaid and Laine, 2006).
Therefore, to minimize major adverse events associated with
aspirin administration such as bleeding and maintain efﬁcacy, the
dose of aspirin approved by theUS Food andDrugAdministration
(FDA) is in the range of 50–325mg/day (Campbell et al., 2007).
An important issue which recently has been discussed exten-
sively is aspirin resistance. The estimated prevalence of aspirin
resistance is 5.5–60%, depending on the type of analyzer and deﬁ-
nition used (Antithrombotic Trialists’ Collaboration, 2002). Some
major cardiovascular disease prevention guidelines do not recom-
mend routine use of platelet function testing in clinical practice.
It is important to keep in mind that stroke recurrence at the
time of taking aspirin does not always equate with aspirin “fail-
ure” (Selim and Molina, 2010). Concomitant use of non-steroidal
anti-inﬂammatory drugs reduces the efﬁcacy of aspirin. The prob-
lem is that most of the current available laboratory methods of
platelet function assays have not been standardized or been shown
to reliably distinguish individual patients at high risk (Eikelboom
et al., 2010).
TRIFLUSAL
Triﬂusal is an antiplatelet agent that is structurally related to
aspirin. It has an antithrombotic effect by acting on various
targets involved in platelet aggregation and vascular inﬂamma-
tory processes. Triﬂusal also increases nitric oxide synthesis in
neutrophils resulting in increased vasodilatory potential. Unlike
aspirin, triﬂusal did not increase bleeding time. In Cochrane
Review the results of ﬁve studies on efﬁcacy of triﬂusal in sec-
ondary stroke prevention were analyzed (four trials after stroke
and TIA, 2944 patients followed for 6–47months and one trial
after acute MI). No signiﬁcant differences were found between
triﬂusal and aspirin for secondary prevention of serious vascular
events in patients with stroke or TIA and acute MI (Costa et al.,
2005). Triﬂusal was associated with a lower risk of hemorrhagic
complications.
Another drug for secondary stroke prevention is ticlopidine, a
thienopyridine derivative. The efﬁcacy of ticlopidine was shown in
placebo-controlled studies. However serious side effects of ticlo-
pidine (bone marrow depression, rash, and diarrhea) put to use a
new drug clopidogrel (Gorelick et al., 2003).
CLOPIDOGREL
Both clopidogrel and ticlopidine are thienopyridine derivative.
Clopidogrel blocks the adenosine diphosphate (ADP) pathway of
platelet aggregation.
Clopidogrel is an inactive prodrug that requires two-step oxi-
dation by the hepatic cytochrome P450 (CYP) system to generate
its active compound, which irreversibly inhibits the ADP P2Y
purinoceptor 12 on circulating platelets. Clopidogrel reaches its
maximum antiplatelet activity within 4–5 days. This should be
taken into accountwhen starting clopidogrel for strokeprevention.
Pharmacokinetic and pharmacodynamic response to clopidogrel
depends on genetic polymorphisms (Mega et al., 2009; Schuldiner
et al., 2009). The genome-wide association study of clopido-
grel response has reported that the loss of function CYP2C19*2
genotype (the most common genetic variant) is associated with
poor metabolism of clopidogrel and poorer outcome (Schuldiner
et al., 2009). The CYP2C19*2 polymorphism accounts for only
12% of variability in clopidogrel platelet response and is asso-
ciated with higher cardiovascular risks. Those are independent
from the diminished conversion of the prodrug to the active form
of clopidogrel. A genomic proﬁle may identify patients at risk of
ischemic event but its use in everyday practice is very limited in
the present time (Holmes et al., 2010).
Tominimize the risk of gastrointestinal bleeding complications,
concomitant administration of clopidogrel with a proton pump
inhibitor (PPIs), also decrease clopidogrel’s antiplatelet action in
a one-third of patients (Siller-Matula et al., 2009). Therefore PPIs
should not be used in combination with clopidogrel.
The efﬁcacy of clopidogrel (75mg daily) in preventing recur-
rent vascular events in patients who suffered a recent MI,
stroke or symptomatic established PAD comparing with aspirin
(325mg daily) was approved in CAPRIE (Clopidogrel vs. Aspirin
in Patients at Risk of Ischemic Events study). CAPRIE was a
large (n = 19,185 patients at 384 clinical centers), a randomized,
blinded, international trial for a mean follow-up of 1.91 years.
Patients were enrolled in three diagnostic strata: ischemic stroke
(6431 patients), MI (6302 patients), and PAD (6452 patients).The
primary end point was risk of non-fatal MI, ischemic stroke, or
vascular death. The rate of the composite outcome per year was
5.32% for clopidogrel and 5.83% for aspirin, or an 8.7% relative
risk reduction (RRR; P = 0.043) favoring clopidogrel (CAPRIE
Steering Committee, 1996).
Themost signiﬁcant difference between clopidogrel and aspirin
was observed in the PAD group (RRR for clopidogrel vs. aspirin,
23.8%; P = 0.0028). In the stroke group, the beneﬁt for clopi-
dogrel was smaller and statistically non-signiﬁcant (RRR 7.3%,
P = 0.28). In the MI group, aspirin had greater efﬁcacy, although
the difference once again was not statistically signiﬁcant (RRR
3.7%; P = 0.56). The results of CAPRIE study suggest greater efﬁ-
cacy for clopidogrel as compared with aspirin after symptomatic
PAD than after MI or stroke (Gorelick et al., 1999). However the
study was not powered to perform sub-group analysis and these
results should be taken with caution. A post hoc analysis of the
CAPRIE data revealed that patients with a history of coronary
artery bypass grafting, who received clopidogrel had an RRR of
28.9% compared with patients receiving aspirin.
Aswell as a grater beneﬁt fromclopidogrel comparing to aspirin
therapy in diabetic patients. The event rate for vascular death,
ischemic stroke, MI, or re-hospitalization or bleeding was 17.7%
in patients with diabetes taking aspirin and 15.6% in patients tak-
ing clopidogrel with absolute risk reduction by 2.1% and number
needed to treat of 48 per year. The adverse event proﬁles for clopi-
dogrel and aspirinwere similar, andboth agentswere relativelywell
tolerated. In CAPRIE the non-fatal primary intracranial hemor-
rhage and hemorrhagic death was less frequent in the clopidogrel
group (0.39%) than in aspirin group (0.53%). Because of the small,
absolute risk reduction of 0.5% (NNT= 200 per year) and the low
cost of aspirin, clopidogrel is not recommended in many countries
as the drug of ﬁrst choice in patients after cerebral ischemia.
Following the success of the CURE study in acute coronary syn-
drome (The Clopidogrel in Unstable Angina to Prevent Recurrent
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Events Trial Investigators, 2001) the next clopidogrel study focused
on stroke prevention was management of atherothrombosis in
high-risk patients with recent TIA or ischemic stroke (MATCH)
trial. It included 7599 patients with recent stroke or TIA and other
vascular risk factors (diabetes or a previous stroke, MI, or PAD)
randomized to treatment with clopidogrel alone or clopidogrel
plus aspirin. The primary outcome was the composite of MI,
ischemic stroke, vascular death, or re-hospitalization for an acute
ischemic event. The combination of aspirin plus clopidogrel treat-
ment group showed favor of the combination (16.73% vs. 15.7%).
The RRR was 6.4% and the result was not statistically signiﬁcant
(P = 0.244). It was observed in this study an approximate three-
fold increased risk of life–threatening (3 vs. 1%; P = 0.0001) and
two-fold increased risk of major (2 vs. 1%; P = 0.0001) bleed-
ing (intracranial or gastrointestinal hemorrhages) in the aspirin
plus clopidogrel group (Diener et al., 2004). MATCH investigators
concluded that the addition of aspirin to clopidogrel in high-risk
stroke and TIA patients did not provide additional clinical beneﬁt
to clopidogrel alone and increased the risk of life-threatening and
major bleeds.
Another RCT, clopidogrel for high atherothrombotic risk and
ischemic stabilization,management, and avoidance (CHARISMA)
tested aspirin 75–162mg/day and clopidogrel 75mg/day or
placebo (Bhatt et al., 2006). There were over 15,000 randomized
patients with symptomatic cardiovascular disease (n = 12,153) or
multiple risk factors (n = 3284; Hankey et al., 2007). The pri-
mary endpoint was the composite of vascular death, non-fatal
stroke, and non-fatal MI. The CHARISMA showed a RRR of 7%
(95% CI, 0.5–17) in favor of the combination of clopidogrel plus
aspirin, but this was not statistically signiﬁcant (P = 0.22; Bhatt
et al., 2006). For the secondary endpoint, which included the pri-
mary endpoint plus hospitalization for unstable angina, TIA, or
a revascularization procedure, a small but statistically signiﬁcant
result favoring the clopidogrel plus aspirin treatment was noted
(RRR 8%; 95% CI, 0.5–14; P = 0.04). An adjudicated ﬁrst stroke
during follow-up (recurrent stroke) occurred in 233 patients, of
whom 103 were randomly assigned clopidogrel and 130 to placebo
(RRR 20%, 95% CI, 3–38). Most strokes were ischemic [n = 202 of
233 (87%); 91 patients assigned clopidogrel vs. 113 on placebo].
A few strokes were hemorrhagic [n = 19 of 236 (8%); 10 clopi-
dogrel vs. 9 placebo]. Only 12 strokes were of unknown type
(Hankey et al., 2010). Non-fatal ischemic stroke was reported
to be reduced in the combination antiplatelet treatment group
but was not statistically signiﬁcant (1.7% vs. 2.1%; RRR 18%,
P = 0.10), and non-fatal stroke was reduced by combination ther-
apy as well (1.9% vs. 2.4%; RRR 20%, P = 0.05). In analysis of the
patients with documented prior MI, ischemic stroke, or sympto-
matic PAD signiﬁcant beneﬁt was observed from dual-antiplatelet
therapy with clopidogrel plus aspirin. Patients with prior stroke
(n = 3245) showed signiﬁcant beneﬁt from aspirin plus clopi-
dogrel (Hazard Ratio 0.78, 95% CI, 0.624–0.976; P = 0.029;
Bhatt et al., 2007).
The fast assessment of stroke and TIA to prevent early recur-
rence (FASTER) trial was designed to test the effectiveness of
combination therapy compared with aspirin alone for prevent-
ing stroke among patients with a TIA or minor stroke within the
previous 24 h. The trial was stopped early because of slow
recruitment. Results were inconclusive (Kennedy et al., 2007).
Initiation of treatment with clopidogrel in a daily dose of 75mg
does not cause maximal platelet inhibition for 5 days (Qureshi
et al., 2000). This delay poses the issue of an early therapeutic
effect for treatment of patients with acute stroke. A bolus dose of
clopidogrel 300mg inhibits platelet aggregation rapidly (Gurbel
et al., 2003).
The efﬁcacy of clopidogrel in secondary stroke prevention was
studied in the atrial ﬁbrillation clopidogrel trial with irbesartan
for prevention of vascular events (ACTIVE A). It was compared
the combination of aspirin plus clopidogrel with aspirin alone
for the prevention of major vascular events in patients with atrial
ﬁbrillation who had an increased risk of stroke and in whom ther-
apy with a vitamin K antagonist was considered to be unsuitable.
The patients were randomly assigned to receive clopidogrel at a
dose of 75mg or matching placebo once daily, in a double-blind
fashion.All patients also received aspirin (recommended dose, 75–
100mg/day). The primary study outcome was any major vascular
event (stroke, non–central nervous system systemic embolism,MI,
or death from vascular causes). The most important secondary
outcome was stroke. At a median of 3.6 years of follow-up, stroke
occurred in 296 patients receiving clopidogrel (2.4% per year)
and 408 patients receiving placebo (3.3% per year; relative risk
0.72; 95% CI, 0.62–0.83; P < 0.001). Major bleeding occurred in
251 patients receiving clopidogrel (2.0% per year) and in 162
patients receiving placebo (1.3% per year; relative risk, 1.57; 95%
CI, 1.29–1.92; P < 0.001; Connolly et al., 2009).
There are several ongoing studies in the efﬁcacy of clopido-
grel in secondary stroke prevention: platelet-Oriented inhibition
in new TIA and minor ischemic stroke (POINT) Trial, clopido-
grel in high-risk patients with acute non-disabling cerebrovascular
events (CHANCE), comparison of triﬂusal and clopidogrel effect
in secondary prevention of stroke based on the cytochrome P450
2C19 Genotyping (MAESTRO), combination of clopidogrel and
aspirin for prevention of early recurrence in acute atherothrom-
botic stroke (COMPRESS; A Service of the US National Institutes
of Health, http://clinicaltrials.gov/ct2/results?term=clopidogrel).
ASPIRIN PLUS EXTENDED-RELEASE DIPYRIDAMOLE
Dipyridamole inhibits the uptake of adenosine into platelets,
endothelial cells, and erythrocytes in vitro and in vivo; the inhibi-
tion occurs in a dose-dependent manner at therapeutic concen-
trations (0.5–1.9mcg/mL). This inhibition results in an increase
in local concentrations of adenosine which acts on the platelet
A2-receptor thereby stimulating platelet adenylate cyclase and
increasing platelet cyclic-3′,5′-adenosine monophosphate levels.
Via this mechanism, platelet aggregation is inhibited in response
to various stimuli such as platelet activating factor, collagen, and
adenosine diphosphate.
The efﬁcacy of aspirin plus extended-release dipyridamole
(ER-DP) was evaluated in the second European stroke preven-
tion study (ESPS-2). ESPS-2 was a randomized, double-blind,
placebo-controlled factorial design study that compared aspirin
25mg twice a day plus ER-DP 200mg twice a day, both agents,
and placebo for secondary prevention in 6602 patients with prior
stroke or TIA followed for 2 years (The ESRS-2 Group. 1997).
Both aspirin and ER-DP monotherapy reduced the risk of stroke
vs. placebo (aspirin: RRR 18%; P = 0.013; ER-DP: RRR 16%,
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P = 0.039). Aspirin and ER-DP reduces also the risk of a compos-
ite stroke or death outcome (aspirin: RRR 13%; P = 0.016; ER-DP:
RRR 15%; P = 0.015). Aspirin plus ER-DP reduced the relative
risk of stroke by 23% compared with aspirin alone (P = 0.001),
and the relative risk of stroke, MI, and sudden death by 20% com-
pared with aspirin alone (P = 0.005). The combination of aspirin
plus ER-DP was twice as efﬁcacious as either agent alone (Diener
et al., 1996).
The most common adverse event associated with ER-DP was
headache. It was observed in 24–70% of patients, usually within
the ﬁrst 3months. Headache is more likely to occur in women,
non-smokers, and patients with an absence of relevant ischemic
lesions on brain imaging (Halkes et al., 2006) Both all-site and
gastrointestinal bleeding were signiﬁcantly more frequent with
aspirin (Diener et al., 1996). In meta-analysis, the results of ESPS-
2 to the nine other placebo-controlled trials does not appreciably
change the relative risk of any major bleeding with aspirin (1.76,
95% CI, 1.45–2.12).
The European/Australasian stroke prevention in reversible
ischemia trial (ESPRIT) was developed in part to answer ques-
tions related to uncertainty over the results of the ESPS-2. ESPRIT
was established and carried out by an academic group in the
Netherlands (Halkes et al., 2006). Budget limitations and the desire
to capture real-life practice situations led to an open-label trial
that compared aspirin with aspirin plus dipyridamole. There were
recruited patients with TIA or ischemic stroke (n = 2739) with a
mean follow-up for 3.5 years. There was a 20% reduction of the
main outcome endpoint (composite of vascular death, non-fatal
stroke, non-fatal MI, or major bleeding) in favor of the aspirin
plus dipyridamole (Ohira et al., 2006). Combination therapy was
safe and did not lead to cardiac complications, which were ﬁnd-
ings similar to those in ESPS-2. Headache was a major reason
for discontinuation of treatment which was also the case with
combination therapy in ESPS-2 (Halkes et al., 2009).
The effects of aspirin plus ER-DP vs. clopidogrel and telmis-
artan in ischemic stroke patients were studied in the prevention
regimen for effectively avoiding second strokes (PRoFESS; Sacco
et al., 2008). It was a double-blind, active, and placebo-controlled
study which included 20,332 patient with a mean follow-up for a
median 2.4 years. The primary endpoint was rate of ﬁrst recurrent
stroke. Recurrent strokes occurred in 916 (9%) patients randomly
assigned to ASA with ER-DP and 898 (9%) patients randomly
assigned to clopidogrel; 880 (9%) patients randomly assigned to
telmisartan and 934 (9%) patients given placebo had recurrent
strokes. Major hemorrhagic events were more common among
patients assigned to aspirin and ER-DP (4.1% compared with
3.6%)but did notmeet statistical signiﬁcance.Adverse events lead-
ing to drug discontinuation (16.4% compared with 10.6%) were
more common among patients assigned to aspirin and ER-DP.
The PRoFESS trial revealed that neither aspirin with ER-DP nor
clopidogrel inﬂuence cognitive and functional outcome, despite
indications from experiments in animals.
ANTIPLATELETS AFTER BLEEDING
According to the recommendations of the American college of
cardiology foundation (ACCF), the American college of gastroen-
terology, and the American heart association (AHA), decision for
discontinuation of ASA in the setting of acute ulcer bleeding after
low-dose aspirin, must be made on an individual basis to discern
potential thrombotic and hemorrhagic complications. Patients
receiving low-dose ASA who develop upper GI bleeding are often
advised to discontinue ASA until ulcers have healed (Bhatt et al.,
2008). There is no evidence that non-ASA antiplatelet drugs such
as clopidogrel will reduce this bleeding risk in the presence of
active ulcers (Lanas et al., 2006).
COMPARISONS
The recommendations of AHA and European stroke organiza-
tion (ESO) for prevention of Stroke and TIA have several differ-
ences concerning class and level of evidence of antiplatelet agent
(Table 1).
For the patients undergoing carotid endarterectomy (CEA)
Aspirin (81–325mg daily) is recommended before CEA and
may be continued indeﬁnitely postoperatively (Class I, Level A).
For the patients undergoing carotid artery stenting (CAS) is
recommended to use before and for a minimum of 30 days after
Table 1 | Recommendations for antiplatelet therapy in secondary stroke prevention for non-cardioembolic ischemic stroke orTIA.
Recommendations ESO AHA
It is recommended that patients receive antithrombotic therapy Class I, Level A Class I, Level A
Initial therapy
Aspirin (50–325mg/day) Class I, Level A Class I, Level A
Combination aspirin 25mg+ER-DP Class I, Level A Class I, Level B
200mg twice a day
Clopidogrel 75mg monotherapy Class I, Level A Class IIA, Level B
Triﬂusal Class I, Level A –
For patients allergic to aspirin, clopidogrel is reasonable – Class IIA, Level B
The combination of aspirin and clopidogrel is not recommended in patients
with recent ischemic stroke, except in patients with speciﬁc indications
(e.g., unstable angina or non-Q-wave MI, or recent stenting)
Class I, Level A Class I, Level A
For patients who have an ischemic stroke while taking aspirin, there is no
evidence that increasing dose of aspirin provides additional beneﬁt
– Class IIB, Level C
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FIGURE 1 | Selection of individual antiplatelet agents.
CAS,dual-antiplatelet therapywith aspirin (81–325mg daily) plus
clopidogrel (75mg daily). For patients intolerant of clopidogrel,
ticlopidine (250mg twice daily) may be substituted. (Class I, Level
C; Brott et al., 2011).
For patients who have an ischemic stroke while taking aspirin,
there is no evidence that increasing the dose of aspirin provides
additional beneﬁt. Unfortunately, there have been any trial to
indicate that switching antiplatelet agents reduces the risk for sub-
sequent events. Although alternative antiplatelet agents are often
considered for non-cardioembolic patients, no single agent or
combination has been studied in patients who have had an event
while receiving aspirin (Ringleb et al., 2008; Furie et al., 2011). The
selection of an antiplatelet agent should be individualized on the
basis of patient risk factor proﬁles (Figure 1).
CONCLUSION
According to the results of the accomplished studies it is difﬁcult
to broadly recommend one antithrombotic agent in favor of the
other. Instead, a review of the currently published data suggests
the importance of focusing on the individualizing approach in
antiplatelet therapy.
Aspirin plus ER-DP or clopidogrel alone may be of more ben-
eﬁt in recurrent stroke prevention than aspirin alone. Clopidogrel
is an alternative for those with allergy to aspirin or gastrointestinal
side effects. For patients who do not tolerate dipyridamole because
of headache, either aspirin or clopidogrel is appropriate.
There are few ongoing trials on new antithrombotic drugs.
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